Enantioselectivity in the methylation of the catecholic phase I metabolites of methylenedioxy designer drugs and their capability to inhibit catechol-O-methyltransferase-catalyzed dopamine 3-methylation.

No abstract is available for this paper.

• Publication year

  2009

• Venue

  Chemical Research in Toxicology

• Publication date

  2009-05-22

• Fields of study

  Medicine, Chemistry

• Identifiers
  DOI 10.1021/tx900134ePMID 19462939
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Stereoselective differences in the cytochrome P450-dependent dealkylation and demethylenation of N-methyl-benzodioxolyl-butanamine (MBDB, Eden) enantiomers.

  2009cited by this paper
• Dopamine- or L-DOPA-induced neurotoxicity: The role of dopamine quinone formation and tyrosinase in a model of Parkinson’s disease

  2009cited by this paper
• The Role of Human Hepatic Cytochrome P450 Isozymes in the Metabolism of Racemic 3,4-Methylenedioxyethylamphetamine and Its Single Enantiomers

  2009cited by this paper
• Catecholestrogens induce oxidative stress and malignant transformation in human endometrial glandular cells: Protective effect of catechol‐O‐methyltransferase

  2008cited by this paper
• Liquid chromatographic-electrospray ionization mass spectrometric assay for simultaneous determination of 3,4-methylenedioxymethamphetamine and its metabolites 3,4-methylenedioxyamphetamine, 3,4-dihydroxymethamphetamine, and 4-hydroxy-3-methoxymethamphetamine in rat brain.

  2008cited by this paper
• The Role of Human Hepatic Cytochrome P450 Isozymes in the Metabolism of Racemic 3,4-Methylenedioxy-Methamphetamine and Its Enantiomers

  2008cited by this paper
• Neurotoxicity mechanisms of thioether ecstasy metabolites.

  2007cited by this paper
• Ecstasy: Are animal data consistent between species and can they translate to humans?

  2006cited by this paper
• The Neuropsychopharmacology and Toxicology of 3,4-methylenedioxy-N-ethyl-amphetamine (MDEA).

  2006cited by this paper
• Drug testing in blood: validated negative-ion chemical ionization gas chromatographic-mass spectrometric assay for enantioselective measurement of the designer drugs MDEA, MDMA, and MDA and its application to samples from a controlled study with MDMA.

  2005cited by this paper
• Stereochemical analysis of 3,4-methylenedioxymethamphetamine and its main metabolites in human samples including the catechol-type metabolite (3,4-dihydroxymethamphetamine).

  2004cited by this paper
• The Role of Metabolism in 3,4-(±)-Methylenedioxyamphetamine and 3,4-(±)-Methylenedioxymethamphetamine (Ecstasy) toxicity

  2004cited by this paper
• Strong inhibitory effects of common tea catechins and bioflavonoids on the O-methylation of catechol estrogens catalyzed by human liver cytosolic catechol-O-methyltransferase.

  2004cited by this paper
• Human pharmacology of MDMA: pharmacokinetics, metabolism, and disposition.

  2004cited by this paper
• Neurotoxicity of MDMA (ecstasy): the limitations of scaling from animals to humans.

  2004cited by this paper
• Enantioselective quantitation of the ecstasy compound (R)- and (S)-N-ethyl-3,4-methylenedioxyamphetamine and its major metabolites in human plasma and urine.

  2003cited by this paper
• Concentrations and ratios of amphetamine, methamphetamine, MDA, MDMA, and MDEA enantiomers determined in plasma samples from clinical toxicology and driving under the influence of drugs cases by GC-NICI-MS.

  2003cited by this paper
• Toxicokinetics of Amphetamines: Metabolism and Toxicokinetic Data of Designer Drugs, Amphetamine, Methamphetamine, and Their N-Alkyl Derivatives

  2002cited by this paper
• Drug testing in blood: validated negative-ion chemical ionization gas chromatographic-mass spectrometric assay for determination of amphetamine and methamphetamine enantiomers and its application to toxicology cases.

  2002cited by this paper
• Determination of MDMA and its metabolites in blood and urine by gas chromatography-mass spectrometry and analysis of enantiomers by capillary electrophoresis.

  2002cited by this paper
• Separation methods for catechol O-methyltransferase activity assay: physiological and pathophysiological relevance.

  2002cited by this paper
• Enantioselective metabolism of the designer drugs 3,4-methylenedioxymethamphetamine ('ecstasy') and 3,4-methylenedioxyethylamphetamine ('eve') isomers in rat brain and blood.

  2002cited by this paper
• Enantio-selective cognitive and brain activation effects of N-ethyl-3,4-methylenedioxyamphetamine in humans.

  2001cited by this paper
• The pharmacology and toxicology of "ecstasy" (MDMA) and related drugs.

  2001cited by this paper
• Stereospecific analysis of ecstasy-like N-ethyl-3,4-methylenedioxyamphetamine and its metabolites in humans.

  2001cited by this paper
• Toxicokinetics and analytical toxicology of amphetamine-derived designer drugs ('Ecstasy').

  2000cited by this paper
• Identification of the human cytochromes P450 involved in the oxidative metabolism of "Ecstasy"-related designer drugs.

  2000cited by this paper
• Glutathione and N-acetylcysteine conjugates of alpha-methyldopamine produce serotonergic neurotoxicity: possible role in methylenedioxyamphetamine-mediated neurotoxicity.

  1999cited by this paper
• Stereospecific analysis and enantiomeric disposition of 3, 4-methylenedioxymethamphetamine (Ecstasy) in humans.

  1999cited by this paper
• 2,5-Bis-(glutathion-S-yl)-alpha-methyldopamine, a putative metabolite of (+/-)-3,4-methylenedioxyamphetamine, decreases brain serotonin concentrations.

  1997cited by this paper
• Oxidation of methamphetamine and methylenedioxymethamphetamine by CYP2D6.

  1997cited by this paper
• Excretion of MBDB and BDB in urine, saliva, and sweat following single oral administration.

  1997cited by this paper
• On the metabolism and the toxicological analysis of methylenedioxyphenylalkylamine designer drugs by gas chromatography-mass spectrometry.

  1996cited by this paper
• Identification of N-methyl-1-(3,4-methylenedioxyphenyl)-2-butanamine (MBDB) in urine from drug users.

  1996cited by this paper
• The demethylenation of methylenedioxymethamphetamine ("ecstasy") by debrisoquine hydroxylase (CYP2D6).

  1994cited by this paper
• Quinone-induced oxidative stress elevates glutathione and induces gamma-glutamylcysteine synthetase activity in rat lung epithelial L2 cells.

  1994cited by this paper
• Metabolism of methylenedioxymethamphetamine: formation of dihydroxymethamphetamine and a quinone identified as its glutathione adduct.

  1990cited by this paper
• Neurotoxic effects of the alpha-ethyl homologue of MDMA following subacute administration.

  1989cited by this paper
• Redox and addition chemistry of quinoid compounds and its biological implications.

  1989cited by this paper
• Derivatives of 1-(1,3-benzodioxol-5-yl)-2-butanamine: representatives of a novel therapeutic class.

  1986cited by this paper
• Differences between the mechanism of action of MDMA, MBDB, and the classic hallucinogens. Identification of a new therapeutic class: entactogens.

  1986cited by this paper
• Kinetic studies on the O-methylation of dopamine by human brain membrane-bound catechol O-methyltransferase.

  1982cited by this paper
• Contribution of Sulfate Conjugation, Deamination, and O‐Methylation to Metabolism of Dopamine and Norepinephrine in Human Brain

  1982cited by this paper
• Oxidative pathways for catecholamines in the genesis of neuromelanin and cytotoxic quinones.

  1978cited by this paper
• Potential oxidative pathways of brain catecholamines.

  1976cited by this paper
• Free radicals in the human nervous system.

  1974cited by this paper

• Toxicological detection of the new psychoactive substances MDPHP and MDPHpP in human urine samples by elucidation of their urinary metabolites using gas chromatography-mass spectrometry.

  2025cites this paper
• Metabolism testing methods as exemplified by selected new psychoactive substances (NPSs)

  2022cites this paper
• Neurological and psychiatric management using COMT inhibitors: A review.

  2019cites this paper
• Development, Applicability, and Comparison of Bioassays for Metabolism of (New) Psychoactive Substances

  2018cites this paper
• In Vitro and In Vivo Metabolite Identification Studies for the New Synthetic Opioids Acetylfentanyl, Acrylfentanyl, Furanylfentanyl, and 4-Fluoro-Isobutyrylfentanyl

  2017cites this paper
• Studies on the metabolism of the fentanyl-derived designer drug butyrfentanyl in human in vitro liver preparations and authentic human samples using liquid chromatography-high resolution mass spectrometry (LC-HRMS).

  2017cites this paper
• Pooled human liver preparations, HepaRG, or HepG2 cell lines for metabolism studies of new psychoactive substances? A study using MDMA, MDBD, butylone, MDPPP, MDPV, MDPB, 5‐MAPB, and 5‐API as examples

  2017cites this paper
• New psychoactive substances: Studies on the metabolism of XLR-11, AB-PINACA, FUB-PB-22, 4-methoxy-α-PVP, 25-I-NBOMe, and meclonazepam using human liver preparations in comparison to primary human hepatocytes, and human urine.

  2017cites this paper
• Inhibition potential of 3,4-methylenedioxymethamphetamine (MDMA) and its metabolites on the in vitro monoamine oxidase (MAO)-catalyzed deamination of the neurotransmitters serotonin and dopamine.

  2016cites this paper
• 1 , 2-Diphenylethylamine Designer Drugs Metabolism Studies and Toxicological Analysis Using Gas Chromatography-Mass Spectrometry and Liquid Chromatography-Mass Spectrometry Coupled to Low and High Resolution-Mass Spectrometry

  2016cites this paper
• Impact of Cytochrome P450 2D6 Function on the Chiral Blood Plasma Pharmacokinetics of 3,4-Methylenedioxymethamphetamine (MDMA) and Its Phase I and II Metabolites in Humans

  2016cites this paper
• Chiral Plasma Pharmacokinetics of 3,4-Methylenedioxymethamphetamine and its Phase I and II Metabolites following Controlled Administration to Humans

  2015cites this paper
• Chiral Plasma Pharmacokinetics of 3,4-Methylenedioxymethamphetamine (MDMA) and its Phase I and II Metabolites following Controlled MDMA Administration to Humans

  2015influential citation
• Development and validation of an LC-MS/MS method after chiral derivatization for the simultaneous stereoselective determination of methylenedioxy-methamphetamine (MDMA) and its phase I and II metabolites in human blood plasma.

  2015cites this paper
• Lefetamine-derived designer drugs N-ethyl-1,2-diphenylethylamine (NEDPA) and N-iso-propyl-1,2-diphenylethylamine (NPDPA): metabolism and detectability in rat urine using GC-MS, LC-MSn and LC-HR-MS/MS.

  2014cites this paper
• The in vivo and in vitro metabolism and the detectability in urine of 3',4'-methylenedioxy-alpha-pyrrolidinobutyrophenone (MDPBP), a new pyrrolidinophenone-type designer drug, studied by GC-MS and LC-MS(n.).

  2014cites this paper
• Studies on the in vivo and in vitro metabolism of the novel psychoactive substance 3',4'-methylenedioxy-alpha-pyrrolidinobutyrophenone (MDPBP)

  2014cites this paper
• Microglial and astroglial activation by 3,4‐methylenedioxymethamphetamine (MDMA) in mice depends on S(+) enantiomer and is associated with an increase in body temperature and motility

  2013cites this paper
• Methylenedioxymethamphetamine-induced neurotoxicity: The role of hepatic enzymes cytochrome p450 2d6 and catechol-o-methyltransferase and contribution of microglia

  2013cites this paper
• Inhibitors of catechol-O-methyltransferase in the treatment of neurological disorders.

  2013cites this paper
• Solid phase extraction for GC-FID determination of 3,4-methylenedioxymethamphetamine (MDMA), 3,4-methylenedioxyamphetamine (MDA) and methamphetamine (MA) in human urine

  2012cites this paper
• Stereoselective urinary MDMA (ecstasy) and metabolites excretion kinetics following controlled MDMA administration to humans.

  2012cites this paper
• Chiral drug analysis using mass spectrometric detection relevant to research and practice in clinical and forensic toxicology.

  2012cites this paper
• Investigations on the stereoselectivity of the phase II metabolism of the 3,4-methylenedioxyethylamphetamine (MDEA) metabolites 3,4-dihydroxyethylamphetamine (DHEA) and 4-hydroxy-3-methoxyethylamphetamine (HMEA).

  2012cites this paper
• Drugs of Abuse (Including Designer Drugs)

  2012cites this paper
• A convenient biomimetic synthesis of optically active putative neurotoxic metabolites of MDMA ("ecstasy") from R-(-)- and S-(+)-N-methyl-α-methyldopamine precursors.

  2012cites this paper
• In vitro approaches to studying the metabolism of new psychoactive compounds.

  2011cites this paper
• Investigation on the Enantioselectivity of the Sulfation of the Methylenedioxymethamphetamine Metabolites 3,4-Dihydroxymethamphetamine and 4-Hydroxy-3-Methoxymethamphetamine using the Substrate-Depletion Approach

  2011cites this paper
• Phase II metabolism of 3,4-methylenedioxymethamphetamine : synthesis, analysis, and enantioselective in vitro and in vivo kinetics

  2011influential citation
• Qualitative studies on the metabolism and the toxicological detection of the fentanyl-derived designer drugs 3-methylfentanyl and isofentanyl in rats using liquid chromatography–linear ion trap–mass spectrometry (LC-MSn)

  2011cites this paper
• Metabolism and Disposition of 3,4-Methylenedioxymethamphetamine (“Ecstasy”) in Baboons after Oral Administration: Comparison with Humans Reveals Marked Differences

  2011influential citation
• Current status of hyphenated mass spectrometry in studies of the metabolism of drugs of abuse, including doping agents

  2011cites this paper
• Urinary excretion kinetics of 3,4-methylenedioxymethamphetamine (MDMA, ecstasy) and its phase I and phase II metabolites in humans following controlled MDMA administration.

  2011cites this paper
• Human MDMA (Ecstasy) and Phase I and Phase II Metabolite Urinary Excretion Kinetics Following Controlled MDMA Administration

  2011cites this paper
• Chiral analysis of amphetamines, methadone and metabolites in biological samples by electrodriven methods

  2011cites this paper
• Development and validation of LC-HRMS and GC-NICI-MS methods for stereoselective determination of MDMA and its phase I and II metabolites in human urine.

  2011cites this paper
• Sulfation of the 3,4-methylenedioxymethamphetamine (MDMA) metabolites 3,4-dihydroxymethamphetamine (DHMA) and 4-hydroxy-3-methoxymethamphetamine (HMMA) and their capability to inhibit human sulfotransferases.

  2011cites this paper
• Chemistry, Pharmacology, and Metabolism of Emerging Drugs of Abuse

  2010cites this paper
• PRECLINICAL STUDY: Atypical development of behavioural sensitization to 3,4‐methylenedioxymethamphetamine (MDMA, ‘Ecstasy’) in adolescent rats and its expression in adulthood: role of the MDMA chirality

  2010cites this paper
• Synthesis and in vitro cytotoxicity profile of the R-enantiomer of 3,4-dihydroxymethamphetamine (R-(-)-HHMA): comparison with related catecholamines.

  2010cites this paper
• Studies on the metabolism of the α-pyrrolidinophenone designer drug methylenedioxy-pyrovalerone (MDPV) in rat and human urine and human liver microsomes using GC-MS and LC-high-resolution MS and its detectability in urine by GC-MS.

  2010cites this paper
• Perspectives of Liquid Chromatography Coupled to Low- and High-Resolution Mass Spectrometry for Screening, Identification, and Quantification of Drugs in Clinical and Forensic Toxicology

  2010cites this paper
• The Role of Human UDP-Glucuronyltransferases on the Formation of the Methylenedioxymethamphetamine (Ecstasy) Phase II Metabolites R- and S-3-Methoxymethamphetamine 4-O-Glucuronides

  2009cites this paper
• Enantiomers of Methylenedioxy Designer Drugs The Role of Cytochrome P 450 s and Catechol-O-methyltransferase in Their Metabolism

  2009cites this paper